An interventional study of Molnupiravir in Viral Infection and COVID-19, sponsored by Valenta Pharm JSC. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Valenta Pharm JSC · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing molnupiravir in COVID-19 — 4 open to participants now, 4 under way, 2 of them phase 3. molnupiravir · COVID-19.
Among the 14 studies testing molnupiravir in COVID-19, this one is the 13th largest by enrollment, is one of 3 that started in 2022, is one of 2 with no phase, and was the 9th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →4 of the 14 studies testing molnupiravir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
University of Liverpool · Sites in South Africa, United Kingdom
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8
First in 2020; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 275 across the 14 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 9 most frequent:
Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
Valenta Pharm JSC has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
2 of the studies testing molnupiravir in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing molnupiravir in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aimed for:
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
This study's enrollment of 37 is below the median of 102 across 4,366 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Valenta Pharm JSC is the lead sponsor of 40 studies on the registry; 18 are open to participants now.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Virus Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withdrawal criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The volunteers will take 1 capsule (200 mg) of Lagevrio (R), 200 mg capsules (Merck Sharp \& Dohme (UK) Limited, UK) in Period 1, and 1 capsule (200 mg) of Molnupiravir (T), 200 mg capsules (Valenta Pharm, Russia) in Period 2.
Drug: Molnupiravir
The volunteers will take 1 capsule (200 mg) of the drug Molnupiravir (T), capsules, 200 mg (Valenta Pharm JSC, Russia) in Period 1, and 1 capsule (200 mg) of the drug Lagevrio (R), capsules, 200 mg (Merck Sharp \& Dohme (UK) Limited, UK) in Period 2.
Drug: Molnupiravir
A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Pharmacokinetics - Cmax
Maximum plasma concentration (Cmax) of β-D-N-4-hydroxycytidine (NHC)
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - tmax
Time to reach Cmax (tmax) of NHC
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - AUC0-t
Area under the plasma concentration-time curve from time 0 to t (AUC0-t) of NHC
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - AUC0-inf
Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) of NHC
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - AUCextr
Extrapolated AUC of NHC, defined as (AUC0-inf - AUC0-t)/AUC0-inf
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - t1/2
Elimination half-life (t1/2) of NHC
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - kel
Elimination constant (kel) of NHC
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Pharmacokinetics - MRT
Mean residence time (MRT) of NHC
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Bioequivalence - ratio of Cmax
Ratio of geometric mean Cmax for NHC after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Bioequivalence - ratio of AUC0-t
Ratio of geometric mean AUC0-t for NHC after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Bioequivalence - ratio of AUC0-inf
Ratio of geometric mean AUC0-inf for NHC after intake of R or T (with 90% confidence intervals)
Time frame: From 0 to 24 hours (Day 1-2 and Day 8-9)
Safety and Tolerability: adverse event (AE) number and frequency
Number and frequency of adverse events (AEs) or serious AEs (SAEs)
Time frame: From the screening (and signing informed consent form) to Day 14 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: adverse event (AE) characteristics
Description and severity of AEs or serious AEs (SAEs), concomitant therapy for AEs/SAEs, causal relationship, outcomes.
Time frame: From the screening (and signing informed consent form) to Day 14 of the study or to an early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - systolic blood pressure (SBP)
SBP, mmHg
Time frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - diastolic blood pressure (DBP)
DBP, mmHg
Time frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - respiratory rate (RR)
RR, breaths per minute
Time frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - heart rate (HR)
HR, beats per minute
Time frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: vital signs - body temperature
Body temperature, centigrade scale
Time frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: physical examination results
Physical examination results
Time frame: Screening, from Day 0 to Day 2, from Day 7 to Day 9, and/or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - color
Color of the urine
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - transparency
Transparency of the urine
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - pH
pH of the urine
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - specific gravity
Specific gravity of the urine
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - nitrites
Nitrites in the urine (+/-)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - protein
Protein in the urine (g/L)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - glucose
Glucose in the urine (mmol/L)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - ketones
Ketones in the urine (mmol/L)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - urobilinogen
Urobilinogen in the urine (mmol/L)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis - bilirubin
Bilirubin in the urine (+/-)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - red blood cells
Red blood cells in the urine (number in sight)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - white blood cells
White blood cells in the urine (number in sight)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - cylinders (except hyaline)
Cylinders (except hyaline) in the urine (number in sight)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: urinalysis (microscopy) - bacteria
Bacteria in the urine (number in sight)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - hemoglobin
Hemoglobin, g/dL
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - red blood cells
Red blood cells, 10\^6/uL
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - hematocrit
Hematocrit, %
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - platelets
Platelets, 10\^3/uL
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - white blood cells
White blood cells, 10\^3/uL
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - erythrocyte sedimentation rate
Erythrocyte sedimentation rate, mm per hour
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - neutrophils
Neutrophils, %
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - lymphocytes
Lymphocytes, %
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - eosinophils
Eosinophils, %
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - monocytes
Monocytes, %
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: complete blood count - basophils
Basophils, %
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - total protein
Total protein in blood serum, g/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - creatinine
Creatinine in blood serum, umol/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - urea
Urea in blood serum, mmol/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - glucose
Glucose in blood serum, mmol/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - total bilirubin
Total bilirubin in blood serum, umol/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - direct bilirubin
Direct bilirubin in blood serum, umol/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - total cholesterol
Total cholesterol in blood serum, mmol/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - triglycerides
Triglycerides in blood serum, mmol/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - alanine transaminase (ALT)
ALT in blood serum, U/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - aspartate transaminase (AST)
AST in blood serum, U/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: blood test results - alkaline phosphatase (ALP)
ALP in blood serum, U/L
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)
12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)
Time frame: Screening, Day 3, Day 9 or on early termination visit within the time frame of the study (from Day 0 to Day 14)
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in May 2022, 0 months.
Of 138 industry-sponsored interventional studies with no phase under COVID-19, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 0 months is below that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molnupiravir